Principal Investigator

Daniel Wanyui
Chan
Awardee Organization

Johns Hopkins University
United States

Fiscal Year
2021
Activity Code
U24
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Clinical and Analytical Validation of Cancer Biomarkers

This proposal is a renewal of our EDRN Biomarker Reference Laboratory (BRL) which is located within the Clinical Chemistry Division (CCD) of the Johns Hopkins Medical Laboratories (JHML) at the Johns Hopkins Hospital. The BRL will continue to serve as a network resource for clinical and laboratory validation of biomarkers, which includes technological development and assay refinement. The JHML are certified by the College of American Pathologist (CAP) and regulated by CLIA (Clinical Laboratory Improvement Amendments of 1988). As such, the JHML follow stringent, good laboratory practice (GLP) guidelines for quality control and quality assurance. The proposed product development will be conducted at the Center for Biomarker Discovery and Translation (CBDT) at The Johns Hopkins University. The project goal is to validate serum proteomic biomarkers, including two biomarkers discovered in our current EDRN BRL developmental study, for the prediction of aggressive prostate cancer in men prior to prostate biopsy. The product "AGPC" is an in vitro diagnostic multivariate index assay (IVDMIA) that combines a panel of biomarkers into a single-valued numerical index score. We have assembled a strong team of research and clinical scientists with many years of experience with cancer biomarkers and in technology development, study design, bioinformatics, validation, and translation. Dr. Chan, the PI, is the Director of both CCD and CBDT. He has over 30 years of experience in clinical chemistry and has conducted many (> 75) research studies funded by industry on cancer diagnostics leading to the approval by the FDA. Since the inception of the EDRN in 2000, five EDRN developed assays have been approved by the FDA for clinical use. Of these five, our BRL led the development of serum OVA1 for ovarian cancer, serum proPSA (phi) for prostate cancer, and served as the reference lab for the urine PCA3 study for prostate cancer. In fact, OVA1 which is based on our original multiplex proteomic study published in Cancer Research, was the first proteomic IVDMIA ever cleared by the FDA for clinical use. In addition, three leading diagnostics/biotechnology companies have agreed to collaborate with us in our product development proposal. In this renewal, we plan to continue our strong commitment to the EDRN mission through network collaborations, and provide leadership in biomarker validation, technology/assay improvement, and product development. With this multi-disciplinary team of scientists, the BRL at Johns Hopkins offers the best opportunity for the success of cancer biomarker validation and translation into the clinic for the early detection of cancer.

Publications

  • Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU international. 2017 Jul;120(1):61-68. Epub 2016 Nov 22. PMID: 27743489
  • Li QK, Shah P, Tian Y, Hu Y, Roden RBS, Zhang H, Chan DW. An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. Clinical proteomics. 2017 May 10;14:16. doi: 10.1186/s12014-017-9152-2. eCollection 2017. PMID: 28491011
  • Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Dec 20;32(36):4066-72. Epub 2014 Nov 10. PMID: 25385735
  • Liang SL, Chan DW. Enzymes and related proteins as cancer biomarkers: a proteomic approach. Clinica chimica acta; international journal of clinical chemistry. 2007 May;381(1):93-7. Epub 2007 Feb 20. PMID: 17382922
  • Toghi Eshghi S, Yang W, Hu Y, Shah P, Sun S, Li X, Zhang H. Classification of Tandem Mass Spectra for Identification of N- and O-linked Glycopeptides. Scientific reports. 2016 Nov 21;6:37189. PMID: 27869200
  • Baycin-Hizal D, Gottschalk A, Jacobson E, Mai S, Wolozny D, Zhang H, Krag SS, Betenbaugh MJ. Physiologic and pathophysiologic consequences of altered sialylation and glycosylation on ion channel function. Biochemical and biophysical research communications. 2014 Oct 17;453(2):243-53. Epub 2014 Jun 24. PMID: 24971539
  • Filson CP, Zhu K, Huang Y, Zheng Y, Newcomb LF, Williams S, Brooks JD, Carroll PR, Dash A, Ellis WJ, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Sokoll LJ, Sanda MG, Chan DW, Lin DW. Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. The Journal of urology. 2022 Nov;208(5):1037-1045. Epub 2022 Jul 5. PMID: 35830553
  • Song J, Zhang Z, Chan DW. Detection of Uveal Melanoma by Multiplex Immunoassays of Serum Biomarkers. Methods in molecular biology (Clifton, N.J.). 2021;2265:447-459. PMID: 33704733
  • Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2019 Jan;28(1):174-182. Epub 2018 Oct 17. PMID: 30333219
  • Li Y, Tao SC, Bova GS, Liu AY, Chan DW, Zhu H, Zhang H. Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Analytical chemistry. 2011 Nov 15;83(22):8509-16. Epub 2011 Oct 26. PMID: 21975078
  • Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, Choi-Miura NH, Goggins M, Chan DW, Zhang Z. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clinical chemistry. 2006 Jun;52(6):1045-53. Epub 2006 Mar 30. PMID: 16574760
  • Toghi Eshghi S, Shah P, Yang W, Li X, Zhang H. GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides. Analytical chemistry. 2015;87(10):5181-8. Epub 2015 May 6. PMID: 25945896
  • Yang W, Laeyendecker O, Wendel SK, Zhang B, Sun S, Zhou JY, Ao M, Moore RD, Jackson JB, Zhang H. Glycoproteomic study reveals altered plasma proteins associated with HIV elite suppressors. Theranostics. 2014 Sep 18;4(12):1153-63. doi: 10.7150/thno.9510. eCollection 2014. PMID: 25285165
  • de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, Siddiqui J, Mosquera JM, Rubin MA, Sanda MG. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. The Journal of urology. 2015 Jul;194(1):65-72. Epub 2015 Jan 28. PMID: 25636659
  • Yang W, Jackson B, Zhang H. Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics. Proteomics. 2016 Jul;16(13):1872-80. Epub 2016 Jun 8. PMID: 27195445
  • Shah P, Zhang B, Choi C, Yang S, Zhou J, Harlan R, Tian Y, Zhang Z, Chan DW, Zhang H. Tissue proteomics using chemical immobilization and mass spectrometry. Analytical biochemistry. 2015 Jan 15;469:27-33. Epub 2014 Oct 2. PMID: 25283129
  • Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. The Journal of urology. 2013 Jul;190(1):70-6. Epub 2013 Jan 9. PMID: 23313212
  • Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, Pavlovich CP. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. The Prostate. 2008 Jun 1;68(8):872-82. PMID: 18361406
  • Wang X, Chen J, Li QK, Peskoe SB, Zhang B, Choi C, Platz EA, Zhang H. Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology. 2014 Oct;24(10):935-44. Epub 2014 Jun 5. PMID: 24906821
  • Harlan R, Zhang H. Targeted proteomics: a bridge between discovery and validation. Expert review of proteomics. 2014 Dec;11(6):657-61. Epub 2014 Oct 28. PMID: 25348939
  • Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert review of proteomics. 2019 Feb;16(2):93-103. Epub 2018 Dec 24. PMID: 30556752
  • Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, Thomas SN, Townsend RR, Zimmerman LJ, Boja E, Chen J, Crimmins DL, Davies SR, Gao Y, Hiltke TR, Ketchum KA, Kinsinger CR, Mesri M, Meyer MR, Qian WJ, Schoenherr RM, Scott MG, Shi T, Whiteley GR, Wrobel JA, Wu C, Ackermann BL, Aebersold R, Barnidge DR, Bunk DM, Clarke N, Fishman JB, Grant RP, Kusebauch U, Kushnir MM, Lowenthal MS, Moritz RL, Neubert H, Patterson SD, Rockwood AL, Rogers J, Singh RJ, Van Eyk JE, Wong SH, Zhang S, Chan DW, Chen X, Ellis MJ, Liebler DC, Rodland KD, Rodriguez H, Smith RD, Zhang Z, Zhang H, Paulovich AG. Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. Clinical chemistry. 2016 Jan;62(1):48-69. PMID: 26719571
  • Zhang B, Tian Y, Zhang Z. Network biology in medicine and beyond. Circulation. Cardiovascular genetics. 2014 Aug;7(4):536-47. PMID: 25140061
  • Sun S, Shah P, Eshghi ST, Yang W, Trikannad N, Yang S, Chen L, Aiyetan P, Höti N, Zhang Z, Chan DW, Zhang H. Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. Nature biotechnology. 2016 Jan;34(1):84-8. Epub 2015 Nov 16. PMID: 26571101
  • Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Dec 1;15(23):7316-21. Epub 2009 Nov 24. PMID: 19934305
  • Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. The Journal of urology. 2008 Aug;180(2):539-43; discussion 543. Epub 2008 Jun 11. PMID: 18550118
  • Toghi Eshghi S, Yang S, Wang X, Shah P, Li X, Zhang H. Imaging of N-linked glycans from formalin-fixed paraffin-embedded tissue sections using MALDI mass spectrometry. ACS chemical biology. 2014 Sep 19;9(9):2149-56. Epub 2014 Jul 30. PMID: 25029481
  • Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecologic oncology. 2007 Dec;107(3):526-31. Epub 2007 Oct 24. PMID: 17920110
  • Thomas SN, Zhang H, Cotter RJ. Application of quantitative proteomics to the integrated analysis of the ubiquitylated and global proteomes of xenograft tumor tissues. Clinical proteomics. 2015 May 20;12(1):14. doi: 10.1186/s12014-015-9086-5. eCollection 2015. PMID: 26019700
  • Yang S, Mishra S, Chen L, Zhou JY, Chan DW, Chatterjee S, Zhang H. Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy. Analytical chemistry. 2015 Oct 6;87(19):9671-8. PMID: 26378618
  • Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA oncology. 2017 Aug 1;3(8):1085-1093. PMID: 28520829
  • Li Y, Shah P, De Marzo AM, Van Eyk JE, Li Q, Chan DW, Zhang H. Identification of glycoproteins containing specific glycans using a lectin-chemical method. Analytical chemistry. 2015;87(9):4683-7. Epub 2015 Apr 20. PMID: 25837443
  • Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. International journal of cancer. 2011 Jul 15;129(2):424-32. Epub 2010 Nov 16. PMID: 20878981
  • Song J, Ma S, Sokoll LJ, Eguez RV, Höti N, Zhang H, Mohr P, Dua R, Patil D, May KD, Williams S, Arnold R, Sanda MG, Chan DW, Zhang Z. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. Theranostics. 2021 Apr 15;11(13):6214-6224. doi: 10.7150/thno.55676. eCollection 2021. PMID: 33995654
  • Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. Journal of proteome research. 2009 Feb;8(2):613-9. PMID: 19035787
  • Eng SE, Basasie B, Lam A, John Semmes O, Troyer DA, Clarke GD, Sunnapwar AG, Leach RJ, Johnson-Pais TL, Sokoll LJ, Chan DW, Tosoian JJ, Siddiqui J, Chinnaiyan AM, Thompson IM Jr, Boutros PC, Liss MA. Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy. Prostate cancer and prostatic diseases. 2024 Mar;27(1):65-72. Epub 2022 Sep 12. PMID: 36097168
  • Sun S, Zhang H. Large-Scale Measurement of Absolute Protein Glycosylation Stoichiometry. Analytical chemistry. 2015 Jul 7;87(13):6479-82. Epub 2015 Jun 15. PMID: 26066578
  • Li D, Chiu H, Chen J, Zhang H, Chan DW. Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. Clinical chemistry. 2013 Jan;59(1):315-24. Epub 2012 Oct 24. PMID: 23099556
  • Song J, Shih IeM, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Nov 15;13(22 Pt 1):6842-9. Epub 2007 Nov 2. PMID: 17982121
  • Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010 May;19(5):1193-200. PMID: 20447916
  • Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. The Journal of urology. 2011 May;185(5):1650-5. Epub 2011 Mar 17. PMID: 21419439
  • Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. The prostate health index selectively identifies clinically significant prostate cancer. The Journal of urology. 2015 Apr;193(4):1163-9. Epub 2014 Nov 15. PMID: 25463993
  • Grill S, Fallah M, Leach RJ, Thompson IM, Hemminki K, Ankerst DP. A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation. Journal of clinical epidemiology. 2015 May;68(5):563-73. Epub 2015 Jan 14. PMID: 25684153
  • Adhikari S, Nice EC, Deutsch EW, Lane L, Omenn GS, Pennington SR, Paik YK, Overall CM, Corrales FJ, Cristea IM, Van Eyk JE, Uhlén M, Lindskog C, Chan DW, Bairoch A, Waddington JC, Justice JL, LaBaer J, Rodriguez H, He F, Kostrzewa M, Ping P, Gundry RL, Stewart P, Srivastava S, Srivastava S, Nogueira FCS, Domont GB, Vandenbrouck Y, Lam MPY, Wennersten S, Vizcaino JA, Wilkins M, Schwenk JM, Lundberg E, Bandeira N, Marko-Varga G, Weintraub ST, Pineau C, Kusebauch U, Moritz RL, Ahn SB, Palmblad M, Snyder MP, Aebersold R, Baker MS. A high-stringency blueprint of the human proteome. Nature communications. 2020 Oct 16;11(1):5301. PMID: 33067450
  • Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, Pavlovich CP. Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. Prostate cancer and prostatic diseases. 2017 Sep;20(3):339-342. Epub 2017 Apr 18. PMID: 28417979
  • Hemken PM, Sokoll LJ, Yang X, Dai J, Elliott D, Gawel SH, Lucht M, Feng Z, Marrero JA, Srivastava S, Chan DW, Davis GJ. Validation of a novel model for the early detection of hepatocellular carcinoma. Clinical proteomics. 2019 Jan 16;16:2. doi: 10.1186/s12014-018-9222-0. eCollection 2019. PMID: 30675135
  • Shih IeM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Müller-Holzner E, Gastl G, Zhang Z, Diamandis EP. Ovarian cancer specific kallikrein profile in effusions. Gynecologic oncology. 2007 May;105(2):501-7. Epub 2007 Feb 15. PMID: 17303231
  • Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology. 2011 Mar;77(3):763.e1-6. Epub 2011 Jan 8. PMID: 21216447
  • Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, Partin AW, Chan DW. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. The Journal of urology. 2009 Mar;181(3):1407-14. Epub 2009 Jan 20. PMID: 19157448
  • Song J, Sokoll LJ, Chan DW, Zhang Z. Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays. Biomedicines. 2021 Dec 14;9. (12). PMID: 34944713
  • Thomas SN, Harlan R, Chen J, Aiyetan P, Liu Y, Sokoll LJ, Aebersold R, Chan DW, Zhang H. Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. Analytical chemistry. 2015 Nov 3;87(21):10830-8. Epub 2015 Oct 21. PMID: 26451657
  • Song J, Merbs SL, Sokoll LJ, Chan DW, Zhang Z. A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma. Clinical proteomics. 2019 Mar 5;16:10. doi: 10.1186/s12014-019-9230-8. eCollection 2019. PMID: 30867659
  • Woolcott CG, Cook LS, Courneya KS, Boyd NF, Yaffe MJ, Terry T, Brant R, McTiernan A, Bryant HE, Magliocco AM, Friedenreich CM. Associations of overall and abdominal adiposity with area and volumetric mammographic measures among postmenopausal women. International journal of cancer. 2011 Jul 15;129(2):440-8. Epub 2010 Nov 16. PMID: 20848591
  • Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Current opinion in oncology. 2014 May;26(3):259-64. PMID: 24626128
  • Meany DL, Sokoll LJ, Chan DW. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert opinion on medical diagnostics. 2009 Nov 1;3(6):597-605. PMID: 19966928
  • Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW. Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. Theranostics. 2015 Jan 1;5(3):267-76. doi: 10.7150/thno.10349. eCollection 2015. PMID: 25553114
  • Höti N, Lih TS, Dong M, Zhang Z, Mangold L, Partin AW, Sokoll LJ, Kay Li Q, Zhang H. Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection. Cancers. 2023 Feb 2;15. (3). PMID: 36765916
  • Liu T, Hossain M, Schepmoes AA, Fillmore TL, Sokoll LJ, Kronewitter SR, Izmirlian G, Shi T, Qian WJ, Leach RJ, Thompson IM, Chan DW, Smith RD, Kagan J, Srivastava S, Rodland KD, Camp DG 2nd. Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. Journal of proteomics. 2012 Aug 3;75(15):4747-57. Epub 2012 Feb 13. PMID: 22846433
  • Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. Biometrical journal. Biometrische Zeitschrift. 2012 Jan;54(1):127-42. Epub 2011 Nov 17. PMID: 22095849
  • Li D, Chan DW. Proteomic cancer biomarkers from discovery to approval: it's worth the effort. Expert review of proteomics. 2014 Apr;11(2):135-6. PMID: 24646122
  • Wang C, Höti N, Lih TM, Sokoll LJ, Zhang R, Zhang Z, Zhang H, Chan DW. Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. Clinical proteomics. 2019 Apr 6;16:13. doi: 10.1186/s12014-019-9234-4. eCollection 2019. PMID: 30996714
  • Liang SL, Lin MT, Hafez MJ, Gocke CD, Murphy KM, Sokoll LJ, Eshleman JR. Application of traditional clinical pathology quality control techniques to molecular pathology. The Journal of molecular diagnostics : JMD. 2008 Mar;10(2):142-6. Epub 2008 Feb 7. PMID: 18258922
  • Sun S, Zhang H. Identification and Validation of Atypical N-Glycosylation Sites. Analytical chemistry. 2015 Dec 15;87(24):11948-51. Epub 2015 Nov 24. PMID: 26593774
  • Wang Y, Lih TM, Höti N, Sokoll LJ, Chesnut G, Petrovics G, Kohaar I, Zhang H. Differentially expressed glycoproteins in pre- and post-digital rectal examination urine samples for detecting aggressive prostate cancer. Proteomics. 2023 Apr;23(7-8):e2200023. Epub 2023 Jan 26. PMID: 36479985
  • Song J, Shih IeM, Chan DW, Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia (New York, N.Y.). 2009 Jun;11(6):605-14, 1 p following 614. PMID: 19484149
  • Song J, Sokoll LJ, Zhang Z, Chan DW. VCAM-1 complements CA-125 in detecting recurrent ovarian cancer. Clinical proteomics. 2023 Jun 25;20(1):25. PMID: 37357306
  • Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010 Dec;19(12):2995-9. Epub 2010 Oct 20. PMID: 20962299